

02-27-2002

FORM PTO-1595
(Rev. 3/01)
OMB No. 0651-0027 (exp. 5/31/2002)



SHEET U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab settings ⇄⇄⇄▽

101994847

▽CPI-000

▽ ▽

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party:

Cadus Pharmaceutical Corporation

2-11-02

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party:

Name: Cadus Technologies, Inc.

Internal Address: _____

Street Address: 767 Fifth Avenue

City: New York State: NY ZIP: 10153

Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance

- Assignment Merger
- Security Agreement Change of Name
- Other _____

Execution Date: December 18, 2001

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

- 1. 08/322,137 (6,100,042)
- 2. 09/309,196

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Peter C. Lauro, Esq.

Internal Address: Lahive & Cockfield, LLP

Street Address: 28 State Street

City: Boston State: MA ZIP: 02109

6. Total number of applications and patents involved:

23

7. Total fee (37 CFR 3.41).....\$ \$920.00

- Enclosed
- Authorized to be charged to deposit account

8. Deposit account number:

12-0080

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Peter C. Lauro, Esq.

Name of Person Signing

Peter C. Lauro

Signature

January 11, 2002

Date

Total number of pages including cover sheet, attachments, and document:

10

02/26/2002 DBYRNE

00000088 00322137

Mail documents to be recorded with required cover sheet information to:
920000 Assignment, Director - U.S. Patent and Trademark Office
Washington, D.C. 20231

01 FC:581

Additional Application/Patent Numbers
CPI-000

A. Patent Application/Patent Numbers

3. 09/286,166
4. 09/143,246
5. 08/461,598 (5,876,951)
6. 09/258,600
7. 08/464,531 (5,789,184)
8. 08/582,333 (6,255,059)
9. 09/747,774
10. 09/953,354
11. 08/946,298
12. 09/201,396
13. 09/581,861
14. 08/732,218 (6,001,553)
15. 08/936,632 (6,159,705)
16. 09/241,888
17. 09/658,765
18. 09/592,010
19. 09/378,046
20. 09/305,923
21. 09/426,332 (6,251,605B1)
22. 09/362,286
23. 09/527,998

GENERAL ASSIGNMENT OF PATENT RIGHTS

WHEREAS, Cadus Pharmaceutical Corporation, a corporation with a place of business at 767 Fifth Avenue, New York, NY 10153 (hereinafter "ASSIGNOR"), is the owner of the entire right, title and interest in and to the patents and patent applications identified in Appendix A hereto;


WHEREAS, ASSIGNOR desires to sell, convey, transfer, assign, and deliver its entire interest in the patents and patent applications identified in Appendix A to its wholly-owned subsidiary, Cadus Technologies, Inc., a Delaware corporation ("ASSIGNEE");

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR, does hereby sell, convey, transfer, assign and deliver to ASSIGNEE the full and exclusive right, title and interest in and to the patents and patent applications identified in Appendix A hereto and any divisional, continuing, reissue or other applications based in whole or in part thereon. This Patent Assignment includes the right to pursue all claims for damages by reason of past infringement of any and all patents listed in Appendix A hereto with the right to sue for, and collect the same for its own use and for the use of its successors, assigns or other legal representatives as fully and entirely as the same would have been enjoyed by ASSIGNOR, if this assignment had not been made.

CADUS PHARMACEUTICAL CORPORATION

By 
Russell D. Glass, President

Sworn to before me and subscribed in my presence this 18th day of December, 2001.


Notary Public

PAUL WOLFSON
NOTARY PUBLIC, State of New York
No. 01WO5024198
Qualified in Westchester County
Commission Expires March 7, 2002

Appendix A to General Assignment of Patent Rights

I. U.S. Applications/Patents

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-012CP3	08/322,137 6,100,042	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	10/13/94 8/8/00 8/8/17	ISSUED
CPI-012CP3CN	09/309,196	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	5/10/99	PENDING
CPI-012CP4BCN	09/286,166	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	4/5/99	PENDING
CPI-012CADVCPA	09/143,246	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	8/28/98 (CPA filed 6/28/00)	PENDING
CPI-012CP4C	08/461,598 5,876,951	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	6/5/95 3/2/99 3/2/16	ISSUED
CPI-012CP4DV	09/258,600	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	2/26/99	PENDING
CPI-012CP4D	08/464,531 5,789,184	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	6/5/95 8/4/98 8/4/15	ISSUED
CPI-012CP5	08/582,333 6,255,059	Methods and Composition for Identifying Receptor Effectors	1/17/96 7/03/01 8/8/17	ISSUED
CPI-012CP5DV	09/747,774	Methods and Composition for Identifying Receptor Effectors	12/21/00	PENDING

U.S. Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing/ Issue Date/ Expiration Date</i>	<i>Status</i>
CP1-012CP7CPACN	09/953,354	Methods and Composition for Identifying Receptor Effectors	9/13/01	PENDING
CP1-012CP8CPA	08/946,298	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/07/97	PENDING
CP1-012CP9	09/201,396	Methods and Compositions for Identifying Receptor Effectors	11/30/98	PENDING
CP1-012C8US	09/581,861	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CP1-014US	08/732,218 6,001,553	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 12/14/99	ISSUED
CP1-031CP2	08/936,632 6,159,705	Methods and Compositions for Identifying Receptor Effectors	9/24/97 12/12/00 9/24/16	ISSUED

U.S. Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-102	09/241,888	Cell Based Signal Generation	2/1/99	PENDING
CPI-122	09/658,765	Yeast Alpha Agglutinins and Use Thereof as Indicators of Activation of the Yeast Pheromone Response Pathway	9/08/00	PENDING
CPI-123	09/592,010	Mating Factor α System for Detection of a Functional Interaction Between A Compound and a Cellular Receptor	6/12/00	PENDING
CPI-088	09/378,046	Cells Having Amplified Signal Transduction Pathway Responses and Uses Therefor	8/30/99	PENDING
CPI-091	09/305,923	Yeast Cells Having Mutations in STP22 and Uses Therefor	5/5/99	PENDING
CPI-096	09/426,332 6,251,605B1	Yeast Cells Having Mutations in CAV1 and Uses Therefor	10/25/99 6/26/01 10/25/19	ISSUED

U.S. Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-099	09/362,286	Expression of G Protein Coupled Receptors with Altered Ligand Binding and/or Coupling Properties	7/27/99	PENDING
CPI-110	09/527,998	Methods for Identifying Target G Protein-Coupled Receptors Using Hidden Markoff Models	3/17/00	PENDING

II. International Applications/Patents

Attorney Docket No.	Serial No./ Patent No.	Title	Filing Date/ Expiration Date/ Issue Date	Status
CPI-012CPAU	64909/94 685103	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 4/30/98 3/23/14	GRANTED
CPI-012CPAUDV2	71696/00	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	11/16/00	PENDING
CPI-012CPCA	2,158,274 2,158,274	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 5/30/00 3/23/14	GRANTED
CPI-012CPEP	94912292.3 0692025	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 10/17/01 3/23/14	GRANTED Registration pending for AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL and SE
CPI-012CPEPDV	98302997.7	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	9/8/98	PENDING
CPI-012CPJP	06-522167	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94	PENDING
CPI-012C8AU	97911/98	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CPI-012C8CA	2305204	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING

CPL-012C8EP	98 95 2143.0	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
-------------	--------------	--	---------	---------

International Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-012C8JP	2000-515008	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CPI-014AU	26354/95 702075	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 5/27/99 4/26/15	GRANTED
CPI-014CA	2,188,950 2,188,950	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 7/03/01 4/26/15	GRANTED
CPI-014JP	528355/95	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95	PENDING
CPI-031C2AU	45930/97	Methods and Compositions for Identifying Receptor Effectors	9/24/97 8/16/01 9/24/17	GRANTED
CPI-031C2CA	2,266,543 733,007	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING
CPI-031C2EP	97 94 4430.4	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING
CPI-031C2JP	10-515880	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING

Two letter country code: AT = Austria; AU = Australia; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EP = Europe (European Patent Convention); ES = Spain; FR = France; GB = Great Britain; GR = Greece; IE = Ireland; IT = Italy; JP = Japan; LU = Luxembourg; NL = Netherlands; SE = Sweden